Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 10,533 matching trials from the local directory fallback.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 2 Interventional

Nightmare Deconstruction and Reprocessing vs. NightWare Wristband

NCT06399874
View directory record Official record
Conditions
Nightmare
Interventions
NightWare, Nightmare Deconstruction and Reprocessing
Device · Behavioral
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
22 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 3:26 PM EDT
Active, not recruiting No phase listed Observational

Endotypic Stability in CRS

NCT06272123
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
no intervention
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 9:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

NCT06200207
View directory record Official record
Conditions
Heart Failure, Systemic Inflammation
Interventions
Placebo, Ziltivekimab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Alexander City, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 3, 2026, 3:31 PM EST
Active, not recruiting Phase 3 Interventional

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574
View directory record Official record
Conditions
Lung Cancer, Non-squamous, Non-small Cell
Interventions
carboplatin, cisplatin, pembrolizumab, pemetrexed, zongertinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Huntsville, Alabama • Bullhead City, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 8:33 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Intensive Computerized Cognitive Training

NCT06130735
View directory record Official record
Conditions
Acquired Brain Injury, Mild Cognitive Impairment, Mild Neurocognitive Disorder
Interventions
Cognitive Computerized Training
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 10:07 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Body Position on Oropharyngeal Swallow Function in Infants

NCT05874102
View directory record Official record
Conditions
Aspiration
Interventions
Sidelying, Upright
Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
38 Weeks to 56 Weeks
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 2:40 PM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

NCT05798663
View directory record Official record
Conditions
NSCLC
Interventions
Atezolizumab, Tiragolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
La Jolla, California • Oakland, California • Roseville, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 6:26 AM EDT
Active, not recruiting Phase 2 Interventional

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

NCT05718869
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Tafasitamab, Zanubrutinib
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Duarte, California • Irvine, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 11:09 AM EDT
Active, not recruiting Phase 2 Interventional

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

NCT05672173
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Ibrutinib, Lisocabtagene Maraleucel, Nivolumab, Pheresis, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 6:15 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

NCT05612178
View directory record Official record
Conditions
HIV-1
Interventions
10-1074-LS, 3BNC117-LS, Sterile Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 3:09 PM EDT
Active, not recruiting Phase 1 Interventional

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

NCT05610891
View directory record Official record
Conditions
High-Grade Glioma
Interventions
CLR 131
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Palo Alto, California • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 6, 2026, 7:15 AM EST
Active, not recruiting No phase listed Observational

ESIS in Pediatric DRE

NCT05469373
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Sarah Katie Ihnen
Other
Eligibility
1 Year to 30 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 4:57 AM EDT
Active, not recruiting Not applicable Interventional

Sodium Lowering Vascular Effects Trial

NCT05388032
View directory record Official record
Conditions
Endothelial Dysfunction, Left Ventricular Dysfunction, Left Ventricular Hypertrophy, Vascular Stiffness
Interventions
Sodium Reduction Intervention
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 7:23 AM EDT
Active, not recruiting Phase 2 Interventional

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT05343013
View directory record Official record
Conditions
Colorectal Cancer
Interventions
TAS-102
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 8:24 PM EDT
Active, not recruiting Phase 2 Interventional

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

NCT05254314
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Semaglutide Pen Injector 2.4mg weekly
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05201638
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
IMU-838 tablets, Placebo matching IMU-838 tablets
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
2
States / cities
Altamonte Springs, Florida • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 2:13 PM EDT
Active, not recruiting Not applicable Interventional

Medication Adherence Program

NCT05183763
View directory record Official record
Conditions
Behavior and Behavior Mechanisms, Hypertension, Medication Adherence
Interventions
Medication reminder tools, STAR-MAP health coaching
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Baton Rouge, Louisiana • Covington, Louisiana • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 2:49 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05134441
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
IMU-838 tablets, Placebo matching IMU-838 tablets
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
6
States / cities
Phoenix, Arizona • West Hollywood, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 9:30 PM EDT
Active, not recruiting Not applicable Interventional

Harmony TPV Post-Approval Study

NCT05077774
View directory record Official record
Conditions
Congenital Heart Disease, Pulmonary Regurgitation, RVOT Anomaly, Tetrology of Fallot
Interventions
Harmony TPV System
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 10:42 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04958265
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Crovalimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
28 Days to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 5:27 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control in Minimize Cognitive Decline

NCT04797403
View directory record Official record
Conditions
Cognitive Decline, Hypertension
Interventions
Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
1,306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 7:30 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Atacicept in Subjects With IgA Nephropathy

NCT04716231
View directory record Official record
Conditions
Berger Disease, IgA Nephropathy
Interventions
Atacicept, Placebo to match Atacicept
Biological · Other
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 7:31 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Acetaminophen, Diphenhydramine, Methylprednisolone, Obinutuzumab, Tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 6:19 AM EDT
Active, not recruiting No phase listed Observational

Fertility, Hypercoagulability, and Inflammation (FREYA) Registry

NCT04537416
View directory record Official record
Conditions
Thrombophilia
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,000 participants
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 1:57 AM EDT